نتائج البحث - "Daniil, Stroyakovskiy"

1

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

المساهمون: Pulmonary Medicine, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Gustave Roussy (IGR), German Center for Lung Research, CHU de Grenoble-Alpes, Moscow City Oncology Hospital, National Stream and Aquatic Ecology Center, Biological and Physical Resources Staff, USDA

المصدر: Journal of Thoracic Oncology, 17(2), 309-323. International Association for the Study of Lung Cancer
JOURNAL OF THORACIC ONCOLOGY
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (2), pp.309-323. ⟨10.1016/j.jtho.2021.09.014⟩

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97d28ac16d7f223dfc27864765b1d672Test
https://doi.org/10.1016/j.jtho.2021.09.014Test

2

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

المصدر: Clinical Cancer Research. 27:5225-5235

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5433fd3a5be3f5bbd73e305a6df55027Test
https://doi.org/10.1158/1078-0432.ccr-21-0809Test

3

Abstract PD12-06: Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial

المصدر: Cancer Research. 81:PD12-06

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Carboplatin, chemistry.chemical_compound, chemistry, Docetaxel, Trastuzumab, Internal medicine, medicine, Amenorrhea, Pertuzumab, medicine.symptom, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::88d84f71b93e4579fa057e9a3897306fTest
https://doi.org/10.1158/1538-7445.sabcs20-pd12-06Test

4

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

المؤلفون: Ralf Gutzmer, Grant A. McArthur, Piotr Rutkowski, Daniil Stroyakovskiy, Anne Uyei, Karl D. Lewis, Kuan Chieh Huang, Thomas Eigentler, Caroline Robert, Lev V. Demidov, Rodrigo Perez Pereira, Georgy M. Manikhas, Paolo A. Ascierto, V. McNally, Svetlana Protsenko, Yibing Yan, Helen Gogas

المصدر: The Lancet. 395:1835-1844

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::6cf2a3be6d2159c5601451efc7ffdca2Test
https://doi.org/10.1016/s0140-6736Test(20)30934-x

5

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 25
Journal of Clinical Oncology

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, Receptor, ErbB-2, medicine.medical_treatment, Docetaxel, Kaplan-Meier Estimate, Ado-Trastuzumab Emtansine, Carboplatin, chemistry.chemical_compound, ErbB-2, 0302 clinical medicine, Trastuzumab, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humanized, Adjuvant, Neoadjuvant therapy, Middle Aged, Neoadjuvant Therapy, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Pertuzumab, RAPID COMMUNICATION, Receptor, medicine.drug, Adult, medicine.medical_specialty, Clinical Sciences, Oncology and Carcinogenesis, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Antibodies, Disease-Free Survival, 03 medical and health sciences, Breast cancer, Internal medicine, Breast Cancer, Chemotherapy, Humans, Oncology & Carcinogenesis, Aged, business.industry, medicine.disease, 030104 developmental biology, chemistry, Trastuzumab emtansine, business

وصف الملف: Print-Electronic; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::108221c07fe98c1622828a09784f0ec6Test
https://doi.org/10.1200/jco.19.00882Test

6

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)

المصدر: Cancers, Vol 13, Iss 2529, p 2529 (2021)
Cancers
Volume 13
Issue 11

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6921260489f81e5cf67d124a56e8ccecTest
https://www.mdpi.com/2072-6694/13/11/2529Test

7

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

المساهمون: National and Kapodistrian University of Athens (NKUA), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Royal Marsden NHS Foundation Trust, N.N. Blokhin Russian Cancer Research Center, Moscow City Oncology Hospital No. 62 [Moscow, Russia] (MCOH), H. Lee Moffitt Cancer Center and Research Institute, European Institute of Oncology [Milan] (ESMO), Veneto Institute of Oncology IOV-IRCCS [Padua, Italy], Maria Sklodowska-Curie National Research Institute of Oncology [Krakow, Poland], Poznan University of Medical Sciences [Poland] (PUMS), Genentech, Inc. [San Francisco], Roche Products Ltd, F. Hoffmann-La Roche [Basel], Massachusetts General Hospital Cancer Center [Boston, MA, USA], Harvard Medical School [Boston] (HMS), Hospital Clinic [Barcelona, Spain], Malbec, Odile

المصدر: Annals of Oncology
Annals of Oncology, 2020, 32 (3), pp.384-394. ⟨10.1016/j.annonc.2020.12.004⟩

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04bd6e100134121fbd8dbf0a9bbc3280Test
https://www.hal.inserm.fr/inserm-03710214Test

8

301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study

المؤلفون: Ralf Gutzmer, Lev V. Demidov, Daniil Stroyakovskiy, Thomas Eigentler, Qian Zhu, Grant A. McArthur, Piotr Rutkowski, Georgy M. Manikhas, V. McNally, Haocheng Li, Rodrigo Perez Pereira, Svetlana Protsenko, Edward McKenna, Helen Gogas, Karl D. Lewis, Caroline Robert, Paolo A. Ascierto

المصدر: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb7ac8f9073746cda014cc45e685919dTest
https://doi.org/10.1136/jitc-2020-sitc2020.0301Test

9

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

المساهمون: Oncology, CCA - Cancer Treatment and Quality of Life, CCA -Cancer Center Amsterdam, Institut Català de la Salut, [Van Cutsem E] University Hospitals Leuven and KU Leuven, Leuven, Belgium. [Danielewicz I] Szpitale Wojewodzkie w Gdyni/Gdansk Medical University, Gdynia, Poland. [Saunders MP] Christie Hospital NHS Foundation Trust, Manchester, UK. [Pfeiffer P] Odense University Hospital, Odense, Denmark. [Argilés G] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Borg C] University Hospital Besançon, Besançon, France, Vall d'Hebron Barcelona Hospital Campus

المصدر: Annals of oncology, 31(9), 1160-1168. Oxford University Press
Scientia
Van Cutsem, E, Danielewicz, I, Saunders, M P, Pfeiffer, P, Argilés, G, Borg, C, Glynne-Jones, R, Punt, C J A, Van de Wouw, A J, Fedyanin, M, Stroyakovskiy, D, Kroening, H, Garcia-Alfonso, P, Wasan, H, Falcone, A, Kanehisa, A, Egorov, A, Aubel, P, Amellal, N & Moiseenko, V 2020, ' Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy : the randomized TASCO1 study ', Annals of Oncology, vol. 31, no. 9, pp. 1160-1168 . https://doi.org/10.1016/j.annonc.2020.05.024Test

مصطلحات موضوعية: 0301 basic medicine, Pyrrolidines, Medicaments antineoplàstics - Ús terapèutic, Phases of clinical research, Gastroenterology, Recte - Càncer - Quimioteràpia, trifluridine/tipiracil, Trifluridine, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, intensive therapy, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, capecitabine, metastatic colorectal cancer, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Trifluridine/tipiracil, Hematology, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES], Bevacizumab, Oncology, 030220 oncology & carcinogenesis, Fluorouracil, Colorectal Neoplasms, medicine.drug, medicine.medical_specialty, TASCO1 study, bevacizumab, Neutropenia, Capecitabine, 03 medical and health sciences, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES], Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Internal medicine, medicine, Humans, Tipiracil, business.industry, medicine.disease, Clinical trial, 030104 developmental biology, chemistry, Quality of Life, business, Thymine, Còlon - Càncer - Quimioteràpia

وصف الملف: Print-Electronic; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5428e52b5139a7b33481be36568a530Test
https://pubmed.ncbi.nlm.nih.gov/32544547Test

10

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

المؤلفون: V. Graupner, Shawn W. Sun, Daniil Stroyakovskiy, Henry J. Conter, Toshiyuki Kozuki, Alan Sandler, Maen A. Hussein, Robert M. Jotte, Ross A. Soo, Federico Cappuzzo, Tien Hoang, Delvys Rodriguez-Abreu, Mark A. Socinski, Kuan Chieh Huang, Marcus Ballinger, Ihor Vynnychenko, Helen Jessop, Mark McCleland

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Paclitaxel, medicine.medical_treatment, Population, Nab-paclitaxel, Antibodies, Monoclonal, Humanized, Carboplatin, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Maintenance therapy, Atezolizumab, Statistical significance, Internal medicine, Albumins, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, education, education.field_of_study, Chemotherapy, business.industry, Hazard ratio, medicine.disease, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Squamous NSCLC, Carcinoma, Squamous Cell, IMpower131, business, Progressive disease

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7028ea64cb2c7c1df21942a04612281eTest
https://essuir.sumdu.edu.ua/handle/123456789/82767Test

تنقيح النتائج